Last week, we saw Numinus Wellness Inc (TSXV: NUMI) commence trading on the TSX Venture Exchange. The company, focused on the use of psychedelic therapies for the treatment of mental health issues, joins a small club of publicly traded companies in the space, which also includes Bruce Linton and Kevin O’Leary-backed Mind Medicine (MindMed) Inc (OTC: MMEDF), and Champignon Brands Inc (OTC: SHRMF).
The public company is a parent to Numinus Bioscience, Numinus Wellness and Numinus R&D:
- Numinus Bioscience is licensed by Health Canada to test, sell, distribute, and eventually conduct research on psychedelic substances.
- Numinus Wellness offers physical locations where psychedelic-assisted therapies can take place once approved by regulators.
- Numinus R&D is where partnerships with leading research groups will take place to advance practice …
Full story available on Benzinga.com